1. Home
  2. BMRC vs CUVL Comparison

BMRC vs CUVL Comparison

Compare BMRC & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bank of Marin Bancorp

BMRC

Bank of Marin Bancorp

HOLD

Current Price

$27.72

Market Cap

436.4M

Sector

Finance

ML Signal

HOLD

Logo Clinuvel Pharmaceuticals Limited American Depositary Shares

CUVL

Clinuvel Pharmaceuticals Limited American Depositary Shares

N/A

Current Price

$5.96

Market Cap

374.2M

Sector

Miscellaneous

ML Signal

N/A

Company Overview

Basic Information
Metric
BMRC
CUVL
Founded
1989
N/A
Country
United States
Australia
Employees
N/A
16
Industry
Major Banks
Miscellaneous
Sector
Finance
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
436.4M
374.2M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
BMRC
CUVL
Price
$27.72
$5.96
Analyst Decision
Buy
Analyst Count
3
0
Target Price
$28.67
N/A
AVG Volume (30 Days)
126.8K
20.4K
Earning Date
04-27-2026
N/A
Dividend Yield
3.92%
N/A
EPS Growth
N/A
N/A
EPS
1.11
N/A
Revenue
N/A
N/A
Revenue This Year
$391.81
N/A
Revenue Next Year
$6.13
N/A
P/E Ratio
$24.68
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.50
$5.90
52 Week High
$30.92
$8.20

Technical Indicators

Market Signals
Indicator
BMRC
CUVL
Relative Strength Index (RSI) 51.11 37.37
Support Level $25.42 N/A
Resistance Level $28.32 $6.89
Average True Range (ATR) 0.74 0.45
MACD 0.11 -0.10
Stochastic Oscillator 84.39 3.33

Price Performance

Historical Comparison
BMRC
CUVL

About BMRC Bank of Marin Bancorp

Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties, and others. The majority of its revenue comes from interest income.

About CUVL Clinuvel Pharmaceuticals Limited American Depositary Shares

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Share on Social Networks: